(+-)-2,3,5,6-Tetrahydro-6-Phenylimidazo(2,1-B)Thiazolemonohydrochloride

Veterinary Oral Drench Formulations and Feed Premix Integration

In commercial ruminant and swine production, (±)-2,3,5,6-Tetrahydro-6-Phenylimidazo(2,1-B)Thiazolemonohydrochloride is incorporated as the active anthelmintic component in aqueous drenches and dry feed premixes targeting gastrointestinal nematodes (Haemonchus contortus, Ostertagia spp., Ascaris suum) and lungworm (Dictyocaulus viviparus). The compound is typically pre-dispersed onto a pharmaceutical-grade lactose or microcrystalline cellulose carrier at 25–30% w/w active loading prior to final blending to achieve a target feed inclusion rate of 15 mg of active base equivalent per kg of bodyweight in cattle and 10 mg/kg in sheep. In dry premix operations, equipment selection becomes critical: horizontal ribbon mixers with a working volume fill ratio of 0.55–0.65 and a Froude number held below 0.4 prevent segregation of the micronized active during discharge. Uniformity of content is verified by sampling 10 locations per batch and analyzing via UV-spectrophotometry at 212 nm against a certified USP reference standard; the coefficient of variation across replicates must not exceed 5.0% as mandated by the VICH GL18 guideline on assay of finished veterinary premixes. A documented processing bottleneck arises from the hygroscopic nature of the hydrochloride salt: at ambient relative humidity exceeding 60%, the active particles form soft agglomerates that resist dispersion in the mixer, requiring preliminary tray drying at 45°C ± 2°C for 90 minutes in a forced-air oven before charging. Pelleted feed applications impose a further thermal boundary. Differential scanning calorimetry reveals an exothermic decomposition onset near 165°C, yet measurable potency loss begins above 70°C in the presence of steam during conditioning. Therefore, pellet mills must operate with a conditioning temperature ceiling of 58°C and retention time below 12 seconds, or manufacturers adopt post-pellet liquid spraying of a concentrated drench formulation onto cooled pellets using a vacuum coater. Finished product shelf-life under high-barrier aluminum foil laminate packaging at 25°C/60% RH is typically 24 months, with a degradation allowance of ≤2% per year as tracked by a stability-indicating HPLC method per ICH Q1A(R2).

What Process Conditions Favor L-Isomer Enrichment During Diastereomeric Salt Resolution?

As the racemic precursor to levamisole hydrochloride, the starting material (±)-2,3,5,6-Tetrahydro-6-Phenylimidazo(2,1-B)Thiazolemonohydrochloride is subjected to classical resolution via diastereomeric salt formation, a process whose yield and enantiomeric excess hinge entirely on the interplay of solvent composition, cation stoichiometry, and crystallization kinetics. The racemic hydrochloride is first converted to the free base by treatment with aqueous sodium hydroxide 30% w/w at 10–15°C, extracted into dichloromethane, and then concentrated under reduced pressure to an oil. To a stirred solution of the free base in isopropanol (5 volumes) at 55°C, L-(-)-dibenzoyl-tartaric acid monohydrate (1.05 molar equivalents) is added in portions over 20 minutes. The resulting clear solution is seeded with 0.5% w/w of authentic L-(-)-tetramisole diastereomeric salt and cooled from 55°C to 3°C at a controlled ramp of 0.3°C/min. Faster cooling rates invariably depress the diastereomeric excess to below 92% de due to kinetically trapped co-crystallization of the undesired D-enantiomer salt. The crystalline solid is isolated on a Nutsche filter fitted with a 10 μm polytetrafluoroethylene cloth, washed with chilled isopropanol (-5°C), and vacuum-dried at 40°C for 8 hours. Enantiomeric purity is determined by chiral HPLC on a CHIRALPAK® IA-3 column with n-hexane/ethanol/diethylamine (90:10:0.1) mobile phase; the required specification for the next reaction step is ≥99.5% ee. The liberated levamisole base is reconverted to the hydrochloride in acetone with anhydrous hydrogen chloride gas at 0–5°C, filtered, and crystallized from methanol/isopropanol to meet Ph.Eur. 10.8 monograph limits for specific optical rotation (between -132° and -137°). Key operational constraints include strict control of water content in isopropanol (≤0.2% Karl Fischer), since water enhances the solubility difference only marginally while promoting hydrolysis of the dibenzoyl-tartaric acid ester, and avoidance of stainless steel 304L equipment during acidification due to trace metal-induced coloration. Typical process yields scale with reaction volume: at 500 L batch size, isolated yields average 72–78% based on racemate, whereas laboratory-scale trials (2 L) can reach 85%. Residual solvent analysis per ICH Q3C must demonstrate isopropanol below 5000 ppm and dichloromethane below 600 ppm.

Immunostimulant Drinking Water Additives in Poultry Production

Medicated drinking water formulations incorporating (±)-2,3,5,6-Tetrahydro-6-Phenylimidazo(2,1-B)Thiazolemonohydrochloride at a target concentration of 100 ppm (expressed as free base) are administered to broiler chickens during the 21–28 day grow-out phase to augment the cellular immune response toward Newcastle disease virus and infectious bronchitis virus live vaccines. The free-flowing water-soluble powder is prepared by cogrinding the active (40% by weight) with anhydrous citric acid (10%), polyvinylpyrrolidone K-30 (5%), and dextrose monohydrate to 100%. Citric acid maintains the solution pH between 4.0 and 4.5 in hard well water (hardness ≤ 250 mg/L CaCO₃), under which condition the racemate remains chemically stable for at least 48 hours at ambient temperature without precipitation. Medication tanks are charged with the reconstituted solution via a 1:100 proportional dosing pump (typical model: DOSATRON® D25RE2) to maintain uniform intake across a bell-drinker or nipple-drinker line; flow-rate calibration before each production cycle is mandatory per the manufacturer's technical bulletin. The withdrawal period before slaughter must be not less than 7 days in the European Union (Commission Regulation (EU) No. 37/2010, Table 1, permitted substance “levamisole,” marker residue sum of levamisole and its metabolites in muscle at 10 µg/kg MRL), and a corresponding withholding period in export markets is calculated from the slope of the depletion curve modeled on a one-compartment open pharmacokinetic model with a terminal half-life of 5.7 hours in plasma. Batch production records retain the temperature profile of the milling step (jet-mill outlet air temperature ≤42°C), since excursions above 50°C can fuse PVP and entrap active particles, reducing dissolution rate and subsequent bioavailability.

When the Imidazothiazole Core Serves as a Building Block for Next-Generation Antiparasitics

Several medicinal chemistry programs use (±)-2,3,5,6-Tetrahydro-6-Phenylimidazo(2,1-B)Thiazolemonohydrochloride as a stable, shelf-ready electrophile precursor for the construction of C-5 and C-6 substituted analogs exhibiting selectivity toward thioredoxin glutathione reductase in Schistosoma mansoni. The hydrochloride is first converted to the free amine under Schlenk-line conditions with rigorously dried triethylamine in tetrahydrofuran, then N-acylated with chloroacetyl chloride at -20°C to give the corresponding α-chloroacetamide in yields exceeding 88% after flash chromatography (silica gel 60 Å, ethyl acetate/hexane). Subsequent nucleophilic displacement with 4-methylpiperazine in acetonitrile under reflux for 6 hours furnishes a piperazinyl-acetamide library member that is isolated as the dihydrochloride salt. The synthetic sequence is validated on 50-gram scale in a jacketed reactor equipped with a retreat-curve impeller operating at 150 rpm; in-process checks by thin-layer chromatography must confirm complete consumption of the chloroacetyl intermediate before workup, because residual alkylating agent generates mutagenic impurities requiring quantitative removal by scavenger resin (MP-TsOH) to stay below the threshold of toxicological concern of 1.5 µg/day per ICH M7. The final drug-candidate hydrochloride is purified by trituration in boiling ethyl acetate, recrystallized from ethanol/water (9:1), and dried in a circulating-air oven at 60°C until constant weight. No toxicological endpoints have been established for these newly derived entities; thus all manipulations are conducted inside an isolator rated for occupational exposure band 3. Manufacturing plants supplying the racemic starting material to such discovery-stage CROs typically pack the product in amber glass bottles with PTFE-lined caps under nitrogen headspace and ship with a REACH-compliant extended safety data sheet that includes an emission scenario for chemical intermediates (ESD ERC 6a).